Researchers develop sequencing platform that generates "clinical-grade" data from small amounts of tumor sample DNA

May 19, 2014 by Bob Yirka, Medical Xpress report

(Medical Xpress)—A large team of researchers with members from several universities and hospitals in the U.S. has developed a sequencing platform that generates "clinical-grade" data using whole exome sequencing (WES) from small amounts of DNA extracted from clinical tumor samples. In their paper published in the journal Nature Medicine, the team describes their new method and how it might soon be used in routine clinical practice.

Over the past several years scientists have learned that different types of cancers with different types of associated tumors can be genetically different from one another and that the different types respond differently to different . Because matching the type of treatment options to tumor types is still so new, researchers are still working out the best ways to go about doing so. Quite often, small samples of tumors are taken which are then genetically tested to see if the genome, or parts of it match known conditions that have been successfully treated using a certain therapy. More recently, it's become clear that WES offers a better approach, it allows for sequencing the whole genome rather than just a part of it. Efforts to do so have, however, been held back by the lack of a method to perform such sequencing on tumor samples stored using fixed in formalin and embedded in paraffin (FFEP), the standard method used to store such samples—it tends to degrade genetic material. In this new effort the researchers came up with a way to use such samples to perform WES.

The breakthrough was the development of an algorithm that is run on a computer that analyses the results of WES—they've named it precision heuristics for interpreting the alteration landscape (PHIAL). It collects genetic data and then sorts it by variation based on already known information about such variations and treatment options for them. It finishes by noting what has been found regarding the genome and by noting treatment options that have been the most successful at treating tumors with similar variations.

The researchers tested their system on 511 actual patients and found it was able to pick out 1,842 alterations out of 250,000 variants for which there are known treatment options. They also found that the system was able to identify clinically relevant alterations in 15 of 16 patients, one of whom was a lung cancer patient who responded positively to a particular therapy after being guided there by the system.

The researchers note that their system allows for expanding the WES knowledgebase—data from their system can be added to an ever increasing database, providing the algorithm ever more information to use in sorting.

Explore further: Fast, simple-to-use assay reveals the 'family tree' of cancer metastases

More information: (Medical Xpress)—Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine, Nature Medicine (2014) DOI: 10.1038/nm.3559

Translating whole-exome sequencing (WES) for prospective clinical use may have an impact on the care of patients with cancer; however, multiple innovations are necessary for clinical implementation. These include rapid and robust WES of DNA derived from formalin-fixed, paraffin-embedded tumor tissue, analytical output similar to data from frozen samples and clinical interpretation of WES data for prospective use. Here, we describe a prospective clinical WES platform for archival formalin-fixed, paraffin-embedded tumor samples. The platform employs computational methods for effective clinical analysis and interpretation of WES data. When applied retrospectively to 511 exomes, the interpretative framework revealed a 'long tail' of somatic alterations in clinically important genes. Prospective application of this approach identified clinically relevant alterations in 15 out of 16 patients. In one patient, previously undetected findings guided clinical trial enrollment, leading to an objective clinical response. Overall, this methodology may inform the widespread implementation of precision cancer medicine.

Related Stories

Fast, simple-to-use assay reveals the 'family tree' of cancer metastases

April 21, 2014
A Massachusetts General Hospital-based research team has developed a simple assay that can reveal the evolutionary relationships between primary tumors and metastases within a patient, information that may someday help with ...

Next-generation sequencing test identified potential targets for pediatric cancer treatments

November 5, 2013
A comprehensive genomic profiling test using next-generation sequencing has identified genomic alterations in more than half of pediatric cancer samples tested that would give clinicians potential targets on which to base ...

Immunogenic mutations in tumor genomes correlate with increased patient survival

April 29, 2014
Developing immunotherapies for cancer is challenging because of significant variability among tumors and diversity in human immune types. In a study published online today in Genome Research, researchers examined the largest ...

Tumor suppressor gene TP53 mutated in 90 percent of most common childhood bone tumor

April 3, 2014
The St. Jude Children's Research Hospital—Washington University Pediatric Cancer Genome Project found mutations in the tumor suppressor gene TP53 in 90 percent of osteosarcomas, suggesting the alteration plays a key role ...

Scientists identify genetic blueprint for cancerous tumors of the appendix

May 12, 2014
Using next generation DNA sequencing, Dartmouth scientists have identified potentially actionable mutations in cancers of the appendix. Their study, "Molecular Profiling of Appendiceal Epithelial Tumors Using Massively Parallel ...

First large-scale study of whole-genome testing helps identify best treatment for women with advanced breast cancer

February 6, 2014
The first large-scale study testing all the DNA—the entire genome—of tumor cells from more than 400 women with advanced breast cancer has identified individuals with a good chance of benefiting from specific treatments ...

Recommended for you

Importance of cell cycle and cellular senescence in the placenta discovered

October 15, 2018
Working with researchers from Stanford University and St. Anna Children's Cancer Research, researchers from Jürgen Pollheimer's laboratory at the Medical University of Vienna's Department of Obstetrics and Gynecology have ...

Team's study reveals hidden lives of medical biomarkers

October 12, 2018
What do medical biomarkers do on evenings and weekends, when they might be considered off the clock?

Researchers find a 'critical need' for whole genome sequencing of young cancer patients

October 12, 2018
St. Jude Children's Research Hospital has re-defined the gold standard for diagnostic testing of childhood cancer patients in the precision-medicine era and has implemented the testing for new cancer patients. The findings ...

Novel genetic study sheds new light on risk of heart attack

October 12, 2018
Loss of a protein that regulates mitochondrial function can greatly increase the risk of myocardial infarction (heart attack), Vanderbilt scientists reported Oct. 3 in the journal eLife.

Study: DNA websites cast broad net for identifying people

October 11, 2018
About 60 percent of the U.S. population with European heritage may be identifiable from their DNA by searching consumer websites, even if they've never made their own genetic information available, a study estimates.

First two papers based on studies using full set of data in the UK Biobank published

October 11, 2018
Two teams of researchers have independently published papers describing research conducted using the full set of data in the UK Biobank—both in the journal Nature. The first team comprised researchers from the U.K., Australia ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet May 19, 2014
This technology combined with IBM's Watson is really going to shake things up.

"With that tumor type we suspect it will respond to drug X because it has the same receptor expression of known types A, B and D which are known to respond to drug X."

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.